Tag: samsung bioepis

samsung bioepis

Latest News

Samsung Epis targets nine additional biosimilars, drug development expansion in growth strategy

Samsung Epis Holdings, the new holding company for Samsung Bioepis, is pursuing a bold expansion strategy focused on pipeline growth, targeting nine additional biosimilars by 2030.

2026.1.15

Samsung Bioepis's headquarters in Songdo is seen in this file photo provided by the company [SAMSUNG BIOEPIS]

Samsung Bioepis wins approval to sell autoimmune biosimilar in Japan

Samsung Bioepis, a biosimilar drug developer under Samsung Group, said Tuesday it has received approval to sell its biosimilar treatment for autoimmune disease in Japan.

2025.12.23

Most popular

Samsung Biologics' factory in Songdo, Incheon [SAMSUNG BIOLOGICS]

Samsung Biologics reports record-breaking $1.1 billion in revenue in Q3

Samsung Biologics reported record earnings for the third quarter, posting more than 1.6 trillion won ($1.1 billion) in revenue, driven by large-scale contract wins with global pharmaceutical firms and strong sales of biosimilars.

2025.10.28

The Samsung Biologics headquarters in Incheon is seen on May 31, 2023. [JOONGANG ILBO]

Samsung to spin off Biologics, put biosimilar subsidiary in holding company to boost CDMO

Samsung Group is striving to strengthen its investments and research and development (R&D) in the bio industry by establishing an intermediate holding company for its bio affiliates, spinning off Samsung Biologics.

2025.5.23

Samsung Biologics' fourth production plant in Songdo, Incheon [SAMSUNG BIOLOGICS]

Samsung Biologics posts record 2024 thanks to biosimilar sales

Samsung Biologics achieved record annual revenue of 4.55 trillion won in 2024, with a 23 percent increase year over year.

2025.1.22

Samsung Bioepis's headquarters in Songdo, Incheon [SAMSUNG BIOEPIS]

Samsung Bioepis's Opuviz gets EC approval

Samsung's biosimilar Opuviz, based on Regeneron Pharmaceutical's vision loss inhibitor Eylea, has been approved for sale in Europe.

2024.11.19

Samsung Biologics CEO John Rim speaks during the annual 42nd J.P. Morgan Healthcare Conference at the main Grand Ballroom in the Westin St. Francis Hotel in San Francisco, California. [SAMSUNG BIOLOGICS]

Court sides with Samsung Biologics over accounting fraud

The Seoul Administrative Court on Wednesday ruled in favor of Samsung Biologics for alleged accounting fraud, canceling a fine imposed on the Korean biotech company by the Financial Services Commission (FSC).

2024.8.14

Samsung Bioepis researchers conduct tests at a lab in Incheon. [SAMSUNG BIOEPIS]

Samsung's Life Science Fund invests in Seattle's Latus Bio

Samsung's Life Science Fund has invested in Seattle's Latus Bio as a new foray into the gene therapy market.

2024.5.3

A researcher at AimedBio, a local biotech company specializing in antibody-drug conjugates technology, looks at a monitor in a lab. The Life Science Fund of Samsung C&T, Samsung Biologics and Samsung Bioepis announced Wednesday that it made an equity investment in the local company. [SAMSUNG BIOLOGICS]

Samsung's Life Science Fund invests in Korean biotech company

Samsung's Life Science Fund has invested in AimedBio, a Korean biotech firm specializing in antibody-drug conjugates. This is the fund's fourth investment and the first in a domestic company.

2023.9.13

Samsung Bioepis headquarters in Songdo, Incheon [SAMSUNG BIOEPIS]

Samsung, Sandoz sign deal to commercialize biosimilar SB17

Samsung Bioepis signed an agreement with Switzerland’s Sandoz for the sales of its Stelara biosimilar drug in the North American and European regions.

2023.9.11